用多功能纳米系统对ROS和HSP进行关键调节,以有效治疗低毒瘤
Bangzhen Ma1,2, Yisheng Zhao3, Xiaoli Liu4
1Shandong Provincial Hospital, Shandong University, Jinan, Shandong, 250021, People's Republic of China.
International journal of nanomedicine
|November 29, 2023
概括
这项研究引入了一种用于协同癌症治疗的新型纳米平台,将光热,光动力学和化学动力学治疗结合起来,以克服瘤耐药性并提高治疗结果.
科学领域:
- 纳米医学是一种纳米医学.
- 生物医学工程 生物医学工程
- 在瘤学瘤学.
背景情况:
- 基于纳米医学的光热疗法 (PTT) 是有前途的,但由于热冲击蛋白 (HSP) 的过度表达而面临挑战,导致热电阻.
- 瘤微环境因素如缺氧和谷氨 (GSH) 阻碍了反应性氧物种 (ROS) 的产生,限制了化学动力学疗法 (CDT) 和光动力学疗法 (PDT).
研究的目的:
- 开发一个多功能纳米平台 (HMPB@TCPP-Cu) 用于协同 PTT/PDT/CDT 克服瘤抵抗.
- 调节ROS和HSP,以提高癌症治疗的疗效.
主要方法:
- 制造HMPB@TCPP-Cu纳米平台,使用空心半孔普鲁士蓝 (HMPB) 作为O2/PTT供应商和TCPP-Cu2+作为PDT/CDT代理.
- HMPB作为一种类似酶的纳米酶,可减少缺氧并增强ROS的产生.
- 2+消耗细胞内GSH,并促进芬顿类反应产生ROS,克服热阻.
主要成果:
- 纳米平台有效地产生氧气,减少瘤缺氧,并增强ROS生产.
- 实现了协同PTT/PDT/CDT,导致显著的ROS升高和消除热阻.
- 试验室和体内研究表明,严重抑制了肝细胞瘤的生长.
结论:
- 开发的多功能纳米平台为克服癌症治疗中的热电阻提供了一个有希望的策略.
- 这种方法为热相关的癌症治疗提供了新的帮助和增强,特别是肝细胞瘤.
相关概念视频
Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K
Regulation of Angiogenesis and Blood Supply
2.6K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.6K


